Cidara Therapeutics Pre-Tax Profit Margin 2014-2022 | CDTX
Cidara Therapeutics pre-tax profit margin from 2014 to 2022. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Cidara Therapeutics Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2022-12-31 |
$0.06B |
$-0.03B |
-45.31% |
| 2022-09-30 |
$0.06B |
$-0.03B |
-54.10% |
| 2022-06-30 |
$0.03B |
$-0.07B |
-244.44% |
| 2022-03-31 |
$0.05B |
$-0.04B |
-77.78% |
| 2021-12-31 |
$0.05B |
$-0.04B |
-85.71% |
| 2021-09-30 |
$0.05B |
$-0.05B |
-102.17% |
| 2021-06-30 |
$0.04B |
$-0.05B |
-114.63% |
| 2021-03-31 |
$0.01B |
$-0.08B |
-690.91% |
| 2020-12-31 |
$0.01B |
$-0.07B |
-608.33% |
| 2020-09-30 |
$0.01B |
$-0.07B |
-650.00% |
| 2020-06-30 |
$0.03B |
$-0.04B |
-162.96% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.072B |
$0.064B |
|
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
|
